Research article · 20 May 2016
EditorialPublished 2011
Carvedilol among Pediatric Patients with Congestive Heart Failure
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Congestive heart failure (CHF) as a result of systemic ventricular dysfunction represents the evolution of many heart disorders in childhood. Among these, dilated cardiomyopathy and some congenital cardiopathies are refractory to the known drug therapy, based on digitalic glycosides, diuretics and converting enzyme inhibitors. For these cases, the last therapeutic resource frequently remains heart transplantation. It is accepted that more than 50% of all children with CHF are candidates for transplantation [1]. However, transplantation involves many impediments, among which the lack of donors is the most important one. If beta-blocking agents were until not long ago contraindicated in patients with CHF, the studies carried out over the past 10 years show that beta-blocking agents improve left ventricular function, the clinical picture of CHF and survival in adults with CHF. A recent consensus on CHF in adults [2] currently recommends beta-blocking agents as part of the standard therapeutic protocol of CHF. This remarkable turn from contraindications to consensus recommendations is due to the deeper understanding of the pathophysiology of heart failure.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 3 May 2019
A clinical study of carvedilol in heart failure Saritha Manem and Nagaveni
Article · 16 Dec 2015
Cellular and molecular mechanisms of the enhanced survival benefits of the Ã?ŽÃ?²I-adrenoceptor biased agonist, carvedilol, in diabetic cardiomyopathy with heart failure: a case report and literature review
Case report · 2015
Cellular and molecular mechanisms of the enhanced survival benefits of the βI-adrenoceptor biased agonist, carvedilol, in diabetic cardiomyopathy with heart failure: a case report and literature review
Article · 3 Apr 2024
Exploring the Latest Advances in Clinical Outcomes for Congestive Heart Failure Patients
More from this journal
The newest in Pharmaceutica Analytica Acta.
Article · 16 Sep 2026
The Fc Domains in the Monoclonal Antibody and Fusion Protein Significantly Boost the Biocomposite Suspension's Power to Combat Harmful Microorganisms, Enhance Drug Delivery, and Improve Protein Stability
Article · 26 Jun 2026
Green Pathways in Drug Quality Assessment: The Growing Role of Sustainable Pharmaceutical Analytics
Article · 26 Jun 2026
Advanced Single-Cell Signal Analysis: The Role of Ghost Cytometry in Cell Therapy Characterization
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Butnariu Angela”
- BylineArticles whose byline prints “Vlase Laurian”
- BylineArticles whose byline prints “Leucuta Sorin”
- BylineArticles whose byline prints “Manuel Chira”
- BylineArticles whose byline prints “Samasca Gabriel”

